Telithromycin (HMR 3647): The first ketolide antibiotic

Drugs of Today

Volumn 37, Issue 9, 2001, Pages 617-628

  Xiong, Y Q ^a   Le, T P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; KETOLIDE; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; MOXIFLOXACIN; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NEUROTOXICITY; NONHUMAN; PHARYNGITIS; PNEUMONIA; REVIEW; SINUSITIS; STRUCTURE ACTIVITY RELATION; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0035196260     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.9.844221     Document Type: Review

References (68)

1. Antimicrobial resistance in Streptococcus pneumoniae: An overview
2. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
3. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae
4. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
5. Emergence of drug-resistant pneumococcal infections in the United States
6. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
7. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use
8. Longitudinal analysis of resistance among Streptococcus pneumoniae (SP) isolated from 100 geographically distributed institutions in the United States during the 1997-1998 and 1998-1999 respiratory seasons
9. Epidemiologie de la resistance aux antibiotiques de Streptococcus pneumoniae en France. Reseau national de surveillance (1984-1993)
10. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
11. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxicillin, cefepime and levofloxacin against Gram-positive clinical isolates in Japan
12. New approaches in the treatment of bacteria infections
13. Ketolides: An advance over macrolides?
14. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent
15. Antimicrobial activity of RU-66647, a new ketolide
16. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)
17. In vitro activities of the new ketolide antibiotics HMR3004 and HMR 3647 against Streptococcus pneumoniae in Germany
18. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria
19. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
20. In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae
21. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans
22. Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis
23. Macrolide resistance among Streptococcus pneumoniae and Streptococus pyogenes isolates from outpatients in the USA
24. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay
25. In vitro activities of ketolides HRM 3647 and HRM 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis
26. In vitro susceptibilities of Bordetellla pertussis and Bordetella parapertussis to two ketokides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycin (rifampin and rifapentine)
27. Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irrespective of penicillin, macrolide or fluoroquinolone resistance
28. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
29. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci
30. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms
31. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens
32. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci
33. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004)
34. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes
35. In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria
36. In vitro activity of HMR 3647 against anaerobic bacteria
37. In vitro activity of telithromycin (HMR 3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan
38. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas
39. Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila
40. Activities of antimicrobial agents against intracellular pneumococci
41. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
42. Antibacterial effect of ketolides HMR 3004 and HMR 3647 against intracellular Legionella pneumophila
43. In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae
44. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4
45. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials
46. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
47. Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers
48. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP)
49. Immunomodulation by antibacterial agents. It is clinically relevant?
50. Investigation of dirithromycin and erythromycin uptake by human neutrophils in vitro
51. Intracellular bioactivity of macrolides
52. Intraphagocytic penetration of macrolide antibiotics
53. Interacions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils
54. The new ketolide HMR 3647 accumulates in the azurophil granules of human polymorphonuclear cells
55. HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae
56. Ketolide treatment of Haemophilus influenzae experimental pneumonia
57. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
58. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae
59. Oral telithromycin (HMR 3647; 800 mg OD) for 7-10 days is well tolerated and as effective as oral trovafloxacin (200 mg OD) for 7-10 days in community-acquired pneumonia (CAP) in adults
60. Efficacy and tolerability of telithromycin (HMR 3647) vs. high-dose amoxicillin in the treatment of community-acquired pneumonia
61. Oral telithromycin (HMR 3647) is well tolerated and as effective as oral clarithromycin (500 mg bid) in community-acquired pneumonia (CAP) in adults
62. Efficacy of telithromycin (HMR 3647), a new ketolide antimicrobial, in community-acquired pneumonia caused by atypical pathogens
63. Oral telithromycin (HMR 3647; 800 mg od) for 5 days is well tolerated and as effective as cefuroxime axetil (500 mg bid) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB)
64. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD
65. Oral telithromycin (HMR 3647; 800 mg od) for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid (500/125 mg tid) for 10 days in acute maxillary sinusitis (AMS) in adults
66. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis
67. Efficacy of 5 days' telithromycin (HMR 3647) vs. 10 days' penicillin V in the treatment of pharyngitis in adults
68. Oral telithromycin (HMR 3647; 800 mg od) for 5 days is well tolerated and as effective as clarithromycin (250 mg bid) for 10 days in group A beta-hemolytic streptococcal pharyngitis/tonsillitis